Paris, 4 December 2025 – Jeantet advised Iris Ventures on the USD 15 million Series B of Innerskin, active in the modern aesthetic medicine sector. Through its 19 centers in France, Innerskin offers a distinctive approach focused on preventative facial and body care, combining high-performance technologies, holistic expertise and premium client experience, by pairing in-clinic services with a range of medical-grade dermatological skincare products.

The investment, led by IRIS Ventures, an international growth fund specialising in next-generation consumer brands in the beauty and wellness sectors, alongside existing investors such as Label Capital, will enable Innerskin to accelerate its expansion across France and Europe.

The Jeantet team comprised Karl Hepp de Sevelinges (Partner, Corporate/M&A), Georges-Dominic Sardi and Emma Rouhaud (Associates, Corporate/M&A).

Download the press release